CVS Health has confirmed a Wall Street Journal report that it is working to establish a tobacco-free pharmacy network and is looking for tobacco-free pharmacies to participate in the new offering.
A new study published Thursday by the Center for Healthcare Supply Chain Research identifies factors, based on an analysis of European models, that may affect the American launch of biosimilars and their marketplace potential in the United States.
H.D. Smith is employing cutting-edge pricing technology through SAP, the wholesaler noted on Tuesday in a video posting.
Healthentic, an analytics company that identifies health savings for employers, found the overall vaccination rate of employees was only 10%.
Big Belli on Thursday announced the December 2014 premiere of a documentary called “40 Weeks.”
The Food and Drug Administration has granted approval to Esbriet (pirfenidone), as well as Ofev (nintedanib), to treat idiopathic pulmonary fibrosis — a condition in which the lungs scar over time.
Specialty pharmacy Burmans last week received the new “Shaping Healthcare Delivery” award at this year’s AmerisourceBergen’s ThinkLive Conference.
As the Food and Drug Administration begins to explore ways to improve its user-fee program for generic drugs, the Generic Pharmaceutical Association and its members have weighed in with suggestions on how to shore up the law to ensure that it helps bring generics to market faster and provides benefits across the entire healthcare system.
Could the regulatory and scientific logjam that’s keeping copycat biotech medicines off the market and out of the hands of patients and health providers in the United States finally be breaking?
What’s in a name? A lot, apparently, if the name applies to a biosimilar medicine.